Dalargin

Dalargin is leu-enkephalin with D-Ala substituted at position 2 to resist enzymatic cleavage and an added C-terminal arginine that makes it too polar to cross the blood-brain barrier on its own. That restriction is the point: you get peripheral opioid receptor activation - reduced gastric acid, accelerated ulcer healing, improved pancreatic and mucosal blood flow, suppression of the stress-induced catecholamine and cortisol surge - without central opioid effects, euphoria, respiratory depression or dependence. It is well known in the drug-delivery literature as the model compound Kreuter used to show that polysorbate-80-coated nanoparticles can smuggle a non-penetrant peptide into the brain, which is where its analgesia-relevant central effects come from. Its place in a cognitive class is by ancestry rather than by nootropic effect.

Targets: Mu opioid receptor (peripheral), Delta opioid receptor (peripheral), Gastric acid secretion, Hypothalamic-pituitary-adrenal stress response

• · A 1 mg ampoule is dissolved in 1 mL of sterile saline. Total course dose in the Russian literature is on the order of 30-50 mg.
• · Diluted in saline and given slowly. This is inpatient use, not something with a home analogue.

Work out your exact syringe units →

• commonTransient hypotension— Most noticeable with rapid intravenous administration. Slow the injection.
• uncommonDizziness or light-headedness— Usually secondary to the blood-pressure drop.
• uncommonInjection-site discomfort
• rareAllergic reaction
• rareHistamine-release flushing— As with other opioid-receptor ligands.

• Pre-existing hypotension - it lowers blood pressure further.
• Pregnancy and breastfeeding - no adequate data.
• Known hypersensitivity to the peptide.
• Do not combine it casually with other blood-pressure-lowering agents or with anaesthetic induction outside a monitored setting.

• synergybpc-157 — Both have gastric and pancreatic protective effects and both come out of the same Eastern European gastroenterology tradition.
• synergykpv — Complementary anti-inflammatory action on gut mucosa by a different pathway.

• · Blood pressure, particularly around intravenous dosing.
• · For pancreatitis use, the usual amylase, lipase and clinical course - Dalargin is an adjunct, not a treatment.

Registered medicine in Russia and some CIS states. Not approved in the US, UK or EU.

• Kreuter et al. 2002, apolipoprotein-mediated transport of dalargin-loaded nanoparticles across the blood-brain barrier (preclinical)

Dalargin is a lesson in how a single added residue can define a drug's entire clinical identity. It is leu-enkephalin with two changes: D-Ala at position 2 to survive aminopeptidases, and a C-terminal arginine whose positive charge makes the molecule too polar to cross the blood-brain barrier. Everything clinically interesting about it follows from the second change. You get peripheral mu and delta opioid receptor activation - reduced gastric acid secretion, accelerated ulcer healing, improved pancreatic and gastric mucosal microcirculation, suppression of the stress-induced catecholamine and cortisol surge around surgery - with no central opioid effects at all. No euphoria, no respiratory depression, no dependence, no analgesia in the usual sense. That is an unusually clean separation and it is the reason Soviet and Russian medicine adopted it for pancreatitis, peptic ulcer and perioperative stress protection rather than for pain. The compound's more famous scientific life is in drug delivery: Kreuter's group used Dalargin as the model compound to demonstrate that polysorbate-80-coated poly(butyl cyanoacrylate) nanoparticles could carry a non-penetrant peptide across the blood-brain barrier, with apolipoprotein adsorption onto the particle surface mediating uptake. Dalargin was chosen for that work precisely because its inability to cross is so reliable that any central effect proves the delivery system worked. Its presence in a cognitive class is an artefact of shared Soviet peptide-pharmacology ancestry, not of any nootropic action - it does not cross into the brain and it has no established cognitive use.

Rapid intravenous administration causes hypotension, and that is the everyday problem - the fix is to slow the injection, not to abandon the dose. Histamine-release flushing happens as it does with other opioid-receptor ligands and is usually benign. The reconstituted solution has no preservative and is a same-day product. The bigger category error is people buying Dalargin expecting a nootropic or an opioid effect, because it sits in a cognitive class and looks like an enkephalin. It is neither. The C-terminal arginine keeps it out of the brain by design; you will feel nothing centrally, and if you do, something is wrong with what you bought. The other realistic failure is using it as a substitute for actual management of acute pancreatitis, which is an inpatient condition with real mortality where a Russian adjunct peptide is not the intervention that matters.

1. 1 mgDay 1, intramuscular — 1 mg from a reconstituted ampoule in 1 mL of saline. Check blood pressure 15 minutes after. This is the standard Russian starting dose for peptic ulcer disease.
2. 2 mgDays 2-21 — 1 mg twice daily. The Russian peptic ulcer course runs 3-4 weeks with a total course dose on the order of 30-50 mg.
3. 5 mgAcute inpatient use only — 1-2 mg two to three times daily intravenously, diluted in saline and given slowly, for 4-6 days during acute pancreatitis or perioperative stress protection. This is a monitored inpatient regimen with no home equivalent.

• Mu opioid receptor (peripheral) — Not quantified in the accessible literature; it is a leu-enkephalin analogue and would be expected to retain enkephalin-like receptor engagement

  Reduced gastric acid secretion, improved mucosal blood flow, accelerated ulcer healing. Peripheral only - the molecule does not reach central receptors.

• Delta opioid receptor (peripheral) — Not quantified; leu-enkephalin is delta-preferring and the analogue is expected to follow

  Contributes to the cytoprotective and microcirculatory effects in pancreas and gastric mucosa.

• Hypothalamic-pituitary-adrenal stress axis — Indirect, via peripheral opioid receptor engagement

  Blunted catecholamine and cortisol surge during surgical stress. This is the perioperative indication and the most mechanistically interesting of its uses.

• Central opioid receptors — Effectively no access - the C-terminal arginine makes the molecule too polar to cross the blood-brain barrier

  None under normal administration. Central effects appear only when the molecule is artificially carried across, as in the nanoparticle delivery studies.

Minutes for the haemodynamic and antisecretory effects - blood pressure changes and gastric acid suppression are essentially immediate after intravenous dosing. The plasma peptide is gone within minutes. Ulcer healing and pancreatitis outcomes play out over a course of days to weeks: the Russian peptic ulcer regimen runs 3-4 weeks at 1-2 mg daily with a total course dose of 30-50 mg, while acute pancreatitis and perioperative use run 4-6 days. There is no chronic use pattern and no reason to construct one.

The sensible pairings are gastrointestinal rather than cognitive. BPC-157 comes out of the same Eastern European gastroenterology tradition and has overlapping gastric and pancreatic protective effects by a different mechanism; KPV acts on gut mucosal inflammation through the melanocortin route. Neither combination has data but both make more sense than anything in the nootropic direction. The interaction that actually matters is haemodynamic: Dalargin lowers blood pressure, and combining it with antihypertensives, with anaesthetic induction agents, or with anything else that drops preload outside a monitored setting is where the real risk sits. Do not think of this as a peptide with an opioid caution - it is a peptide with a blood pressure caution. On the opioid side, because it does not reach central receptors, it neither potentiates opioid analgesia nor precipitates withdrawal, and it will not show up as an opioid effect in any way you would notice.

Against a proton pump inhibitor for peptic ulcer disease, which is the honest comparison for its main indication: omeprazole and its relatives have overwhelming replicated evidence, are oral, cost pennies and are available everywhere. Dalargin is an injectable with a Russian-language literature that does not meet modern standards. There is no scenario in which Dalargin is the better choice for an ulcer. Against BPC-157: both are Eastern European gastroprotective peptides, both have thin evidence by Western standards, but Dalargin has actual clinical use in a registered indication and a defined mechanism, while BPC-157 has rodent studies and forum consensus. That comparison favours Dalargin more than most people assume. Against anything else in this cognitive class: it does not belong here. It does not cross the blood-brain barrier, has no established nootropic effect, and its inclusion reflects shared Soviet peptide-pharmacology ancestry rather than any cognitive action. If you came to this page looking for a nootropic, this is not one.

$40–$150/month. Ampoules from Russian or CIS pharmacy sources are inexpensive per unit - typically 1-3 USD for a 1 mg ampoule - so a 3-4 week peptic ulcer course at 1-2 mg daily runs 40-120 USD. The cost barrier is not the price but the difficulty of legally importing an injectable prescription medicine that is not approved in the West.

• ?No published receptor binding affinities for Dalargin at mu or delta opioid receptors that I could resolve.
• ?The 0.1 hour half-life in the Core record reflects the general statement that the peptide is degraded within minutes; I could not locate a primary pharmacokinetic study giving a measured value.
• ?No bioavailability, volume of distribution, clearance or protein binding data exists.
• ?The Russian clinical literature on pancreatitis and peptic ulcer is substantial in volume and does not meet modern methodological standards. I could not verify any individual trial.
• ?The degree to which the blood-brain barrier exclusion is absolute versus merely very high is not quantified - the nanoparticle work assumes it is complete enough to serve as a negative control, which is a strong practical statement but not a measured percentage.
• ?Whether the perioperative stress-protection effect is clinically meaningful, as opposed to a measurable change in cortisol and catecholamines, has not been established in any trial I could verify.
• ?The molecular weight of 725.8 Da in the Core record is plausible for the described hexapeptide but I did not verify it against a primary characterisation.

• Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R, Journal of Drug Targeting, 2002 · PMID 12164380

  The study that made Dalargin famous outside Russia. It was used as the model non-penetrant peptide to prove that polysorbate-coated nanoparticles carry drugs across the blood-brain barrier via apolipoprotein adsorption. Read it for the delivery science, not for Dalargin as a therapeutic.

• Nanoparticulate systems for brain delivery of drugs Kreuter J, Advanced Drug Delivery Reviews, 2001 · PMID 11251246

  The broader review of the nanoparticle brain-delivery programme in which Dalargin was the workhorse test compound. Useful context for why a gastroenterology drug keeps appearing in neuroscience papers.